Abstract
Limited experience is available on the feasibility and efficacy of autologous stem cell transplantation (ASCT) in elderly patients with non-Hodgkin's lymphoma (NHL). In 1994–2004 altogether 88 NHL patients>60 years old received ASCT in six Finnish transplant centres. There were 57 male and 31 female patients with a median age of 63 years (range 60–70 years); 17 patients were>65 years. The histology included diffuse large B cell (n=29), mantle cell (n=27), follicular (n=15), peripheral T cell (n=12) and other (n=5). Disease status at ASCT was I complete remission/partial remission (CR/PR) in 53 patients, II CR/PR in 30 patients and other in five patients. The conditioning regimens included BEAC (n=49), BEAM (n=34), TBI-CY (n=4) and other (n=1). Eighty-four patients received PB grafts. The medians to reach neutrophils>0.5 and platelets>20 were 10 and 14 days, respectively. The early treatment-related mortality (TRM) (<100 days) was 11%. With a median follow-up of 21 months for all patients, 45 patients (51%) are alive. A relapse or progression after ASCT has been observed in 32 patients (36%). ASCT is feasible in selected elderly patients with NHL, but the early TRM seems to be higher than in younger patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Goss PR . Non-Hodgkin's lymphoma in elderly patients. Leuk Lymphoma 1993; 10: 147–156.
Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller TP, Grozea PA et al. Effect of age on therapeutic outcome in advanced histiocytic lymphoma. J Clin Oncol 1986; 4: 295–305.
Vose JM, Armitage JO, Weisenburger DD, Bierman PJ, Sorensen S, Hutchins M et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838–1844.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.
Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641.
Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.
Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295.
Geisler C, Elonen E, Kolstad A, Laurell A, Andersen NS, Pedersen L et al. Nordic Mantle Cell Lymphoma (MCL) Project: Prolonged follow-up of 86 patients treated with BEAM/BEAC+PBSCT confirm that addition of high-dose AraC and rituximab to CHOP induction+in vivo purging with rituximab increases clinical and molecular response rates, pcr-negative grafts, failure-free, relapse-free and overall survival. Blood 2004; 104: 6a (abstr).
Guba SC, Vesole DH, Jagannath S, Bracy D, Barlogie B, Tricot G . Peripheral stem cell mobilization and engraftment in patients over age 60. Bone Marrow Transplant 1997; 20: 1–3.
Stamatoullas A, Fruchart C, Khalfallah S, Buchonnet G, Contentin N, Bastit D et al. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplant 1997; 19: 31–35.
Moreau P, Milpied N, Voillat L, Colombat P, Mahe B, Rapp MJ et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61–65 years: a pilot study. Bone Marrow Transplant 1998; 21: 1193–1196.
Mazza P, Palazzo G, Amurri B, Cervellera M, Manna N, Fellini G et al. Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: an interim report. Bone Marrow Transplant 1999; 23: 1273–1278.
Jantunen E, Mahlamäki E, Nousiainen T . Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol. Bone Marrow Transplant 2000; 26: 737–741.
Leger CS, Bredeson C, Kearns B, Bence-Bruckler I, Atkins H, Huebsch L . Autologous blood and marrow transplantation in patients 60 years and older. Biol Blood Marrow Transplant 2000; 6: 204–210.
Olivieri A, Capelli D, Montanari M, Brunori M, Massidda D, Poloni A et al. Very low toxicity and good quality of life in 48 elderly patients autotransplanted for haematological malignancies: a single centre experience. Bone Marrow Transplant 2001; 27: 1189–1195.
Zallio F, Cuttica A, Caracciolo D, Gavarotti P, Bergui L, Giaretta F et al. Feasibility of peripheral blood progenitor cell mobilisation and harvest to support chemotherapy intensification in elderly patients with poor prognosis non-Hodgkin's lymphoma. Ann Hematol 2002; 81: 448–453.
Bitran JD, Klein L, Link D, Kosirog-Glowacki J, Stewart C, Raack D et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003; 9: 383–388.
Villela L, Sureda A, Canals C, Sanz Jr MA, Martino R, Valcarcel D et al. Low transplant-related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. Haematologica 2003; 88: 300–305.
Gopal AK, Gooley TA, Golden JB, Maloney DG, Bensinger WI, Petersdorf SH et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593–599.
de la Rubia J, Saavedra S, Sanz GF, Martin G, Moscardo F, Martinez J et al. Transplant-related mortality in patients older than 60 years undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 27: 21–25.
Andersen NS, Pedersen L, Elonen E, Johnson A, Kolstad A, Franssila K et al. for the Nordic Lymphoma Group. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003; 71: 73–80.
Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E, Lopez-Guillermo A, Gisselbrecht C et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003; 120: 793–800.
Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R et al. Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677–2684.
Martelli M, Vignetti M, Zinzani PL, Cherlinzoni F, Meloni G, Fiacchini M et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front line chemotherapy: a prospective randomized Italian multicenter study. J Clin Oncol 1996; 14: 534–542.
Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 586–592.
Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective LNH 87-2. J Clin Oncol 1997; 15: 1131–1137.
Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.
Verdonck LF, van Putten WLJ, Hagenbeek A, Schouten HC, Sonnevelt P, van Imhoff GW et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045–1051.
Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordjik FM et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomised phase III EORTC study. J Natl Cancer Inst 2001; 93: 22–30.
Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472–2479.
Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H et al. Randomized study to evaluate the use of high-dose therapy as a part of primary treatment for ‘aggressive’ lymphoma. J Clin Oncol 2002; 20: 4413–4419.
Martelli M, Gherlinzoni F, De Renzo A, Zinzani PL, De Vivo A, Contonetti M et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol 2003; 21: 1255–1262.
Spielberger R, Stiff P, Bensinger W, Gentile T, Weisdorf D, Kewalramani T et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351: 2590–2598.
Acknowledgements
The study was supported by a grant from the Blood Disease Research Foundation of Finland.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jantunen, E., Itälä, M., Juvonen, E. et al. Autologous stem cell transplantation in elderly (>60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 37, 367–372 (2006). https://doi.org/10.1038/sj.bmt.1705266
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705266
Keywords
This article is cited by
-
Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis
Bone Marrow Transplantation (2023)
-
High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma
Current Oncology Reports (2015)
-
Safety and feasibility of high-dose ranimustine (MCNU), carboplatin, etoposide, and cyclophosphamide (MCVC) therapy followed by autologous stem cell transplantation for malignant lymphoma
International Journal of Hematology (2012)
-
High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma
Bone Marrow Transplantation (2011)
-
Progress in treatment of peripheral T-cell lymphoma with hematopoietic stem cell transplantation
The Chinese-German Journal of Clinical Oncology (2011)